I hope you are right for the sake of longs still in this stock. It's a little odd that Dr. Said, and emergency medicine doctor, is doing this procedure but then again compensation for that speciality is not ideal. But I do not believe they have seen the trial data. If I had to guess I would bet that only Dr. Rajfer and the company know the clinical trial results. Many doctors won't get involved in any procedure or device without getting the clinical trial data first. But many will despite the concerns that should raise. I have done medical research for 20 years and every surgeon I worked with would never do a new procedure before seeing clinical trial data / proof it is effective and safe first. The caveat for CMTH is they are in the stem cell field there is a lot of soft science (pardon the pun) in most applications especially in regenerative medicine. Most stem cell companies are doing procedures unsupported by clinical trials or any good evidence. I think thats where CMTH falls from what I have seen over the past year and resistance to report their data. Also I wonder what conflicts of interest all of the doctors have who are doing these procedures including Dr. Rajfer. What interests do they have in the company, stock, consultant positions, members of the board, etc. There are way too many stem cell clinics currently making unsubstantiated claims.
I am not suggesting this company is a scam though. For me I can not yet assess whether or not that is the case; at least yet. I can only say from my own experience and knowing too much about medical research and clinical trials I could not justify owning stock in this company any longer. Hopefully the science actually works in their Caverstem application, clinical trial is reported soon, and things reverse with their trajectory and start scaling rapidly. Thats a big ask though
News 
Market Data 
Discover 
